Liver specific transcriptional enhancer
US7179903B2 · kind B2 · utility
41Cited by
20References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 6, 2004 |
| Grant date | Feb 20, 2007 |
| Priority date | — |
| Expiry date | Mar 11, 2025 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2830/15
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Recombinant lentiviruses and transfer vectors for transgene delivery as well as methods for gene therapy using such vectors are disclosed. The invention provides a third generation lentiviral packaging system and a set of vectors for producing recombinant lentiviruses, as well as novel tissue specific enhancer and promoter elements useful for optimizing liver specific transgene delivery. The transgene is preferably a blood clotting factor such as human factor IX (hFIX) or human factor VIII (hFVIII) and can be used for treatment of hemophilia.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.